leucovorin

Overview

Folinic acid; potentiates fluorouracil thymidylate synthase inhibition in FOLFOX/FOLFIRI/FOLFIRINOX regimens.

Evidence in the corpus

  • Component of colorectal-style first-line regimens evaluated in appendiceal adenocarcinoma; GNAS-mut predominant MAAP had only 6% first-line response rate vs 50% for RAS-mut predominant MAAP on such leucovorin/5-FU-based therapy (P=.03) PMID:36493333.
  • Leucovorin is a component of FOLFIRINOX (fluorouracil + irinotecan + oxaliplatin + leucovorin), used in 38% of the curated 1,480-patient MSK PDAC cohort as first-line systemic therapy; chemotherapy backbone choice was not significantly associated with OS in 304 metastatic patients PMID:39753968.
  • Mentioned in HCC comprehensive molecular landscape review as part of chemotherapy context for hepatocellular carcinoma systemic treatment PMID:24798001

Resistance mechanisms

  • GNAS-mut predominant MAAP is the chemotherapy-resistant molecular subtype with respect to 5-FU/leucovorin backbones PMID:36493333.

Cancer types (linked)

  • APAD
  • PAAD — pancreatic adenocarcinoma (FOLFIRINOX component)

Sources

This page was processed by crosslinker on 2026-04-30. - PMID:24798001

This page was processed by wiki-cli on 2026-05-11.